Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003467 · ClinicalTrials.gov registry record · Phase 2

Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma

A Phase 2 study, sponsored by Duke University.

Completed
Registry status
Phase 2
Development phase
68
Enrollment target

NCT00003467: Completed Phase 2 study, sponsored by Duke University.

NCT00003467 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 68 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003467, a Phase 2 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 2
Development phase
68 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.

Interventions

  • DRUG carmustine
  • PROCEDURE surgical procedure
  • DRUG polifeprosan 20 with carmustine implant

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 1998-01
Est. Completion 2004-02
Phase Phase 2
Duke University

1,725 total trials

What the finished NCT00003467 record still lists

NCT00003467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (49% lower).

The record links to 0 conditions, and to 3 interventions - of which carmustine is the first listed.

NCT00003467 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003467 about?

NCT00003467 is a clinical study titled "Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with recurrent supratentorial low-grade glioma.

What is the current status of trial NCT00003467?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 1998-01. Estimated completion is 2004-02.

What interventions are being tested in trial NCT00003467?

The interventions under investigation include: carmustine (DRUG), surgical procedure (PROCEDURE), polifeprosan 20 with carmustine implant (DRUG).

Who is sponsoring clinical trial NCT00003467?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00003467's enrollment target sits among peer trials

68 967th of 2000 higher than 1,027 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02044497 · 68 participants · Phase 4

    Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  • NCT03779854 · 68 participants · Phase 2

    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  • NCT03821246 · 68 participants · Phase 2

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

  • NCT04115514 · 68 participants · Phase 2

    Treatment of ARDS With Instilled T3

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003467, the US trial registry maintained by the National Library of Medicine. NCT00003467 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.